Tuesday, 29 April 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 29 April 2025
News

Big name drugs win expansions

Posted 18 December 2023 AM

The PBAC considered 18 change to listing requests at its November meeting, with some big names getting the nod.

Sanofi scored a win, with PBAC recommending immunotherapy Libtayo as a first line treatment in combination with platinum doublet chemotherapy for people with stage IV non-small cell lung cancer with no evidence of epidermal growth factor receptor, anaplastic lymphoma kinase, or c-ROS-proto-oncogene 1 aberrations. This joins another recommendation for NSCLC given a year ago, but not acted upon.

To see the whole article, please login

Popular

Yes... but with a price reduction
Approval tainted by PBAC 'No'
Finally, a PBS listing after 1514 days
One submission wonder hits PBS
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home